Plasticell signs technology agreement with Sigma-Aldrich: Collaboration to produce novel turnkey solution for stem cell research
Advertisement
Plasticell has announced the signing of a collaboration agreement with Sigma-Aldrich, a leading provider of technologies and reagents to the life science research market.
In the collaboration, Sigma-Aldrich will use its CompoZr® Zinc Finger Nuclease Technology to engineer various human stem cell lines that enable tracking of differentiation to specific mature cell types via fluorescent reporters, integrated directly into developmentally expressed genes. The technology enables highly efficient, precisely targeted knock-in of reporters, resulting in more reliable reporter systems than conventional transgenic methods which integrate reporters randomly throughout the genome. Plasticell will then use these cell lines in its CombiCult™ high throughput screening (HTS) system to develop novel stem cell differentiation protocols.
Under the Agreement, Plasticell will own resulting protocols for high efficiency, directed differentiation of stem cells, with Sigma-Aldrich marketing the reporter stem cell lines. Cells and media may be commercialised together in kits, while reporter cell lines can be linked to specific CombiCult™ screens, for optimised differentiation of human embryonic stem cells (ESC) or induced pluripotent cells (iPSC).
Financial terms were not disclosed.
Other news from the department business & finance
These products might interest you
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
Last viewed contents
New blood tests promise simple, cost-effective diagnosis of gastrointestinal cancers